PCN80 Comparative Analysis of Cost-Effectiveness Bevacizumab + Paclitaxel Versus Using Only Versus Paclitaxel as First Line Treatment of Patients with Metastatic Breast Cancer in Mexico Public Insurance (Seguro Popular)  by Arreola Ornelas, H. et al.
bined with current cervical cancer screening and HPV disease treatment practices
in Turkey. For the vaccination strategy 85% coverage rate was assumed in the
frame of a mandatory school-based program. Reference strategy was current cer-
vical cancer screening and HPV disease treatment practices in Turkey. Costs were
estimated from the perspective of the Turkish healthcare system, using direct
medical costs associated with the diagnosis and treatment of cervical diseases.
RESULTS: Over 100 years, cumulative % (absolute) reduction in the incidence of
6/11/16/18-related cases of CIN1, CIN2/3, cervical cancer, cervical cancer deaths,
genital warts-female, and genital-warts-male was 78% (4,894), 72% (32,537), 57%
(73,277), 54% (40,513), 86% (404,674), and 86% (409,029), respectively, in the vacci-
nation group compared to the reference group. Number of 6/11/16/18-related CIN1,
CIN2/3, cervical cancer, cervical cancer deaths, and genital warts (both in female
and male population) was halved in the vaccination strategy group compared to
the reference strategy group by year 19, 24, 41, 44, and 14, respectively. The incre-
mental cost-effectiveness ratio for routine vaccination of 12-year-old girls was
18,251 TRY/QALY over 100 years. CONCLUSIONS: A quadrivalent HPV vaccination
program can reduce the incidence of cervical cancer, CINs and genital warts in
Turkey at a cost-per-QALY ratio within the range defined as cost effective.
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OBJECTIVES: Sarcomas are rare tumours (1-2% of all cancers) with high discor-
dance in diagnosis and low compliance with clinical practice guidelines (CPG). The
objective was then to perform a cost-effectiveness analysis (CEA) of compliance
with CPG compared to non compliance in the treatment of sarcoma. METHODS:
The study included patients aged15 years with histological diagnosis of sarcoma
treated at the University hospital of Lyon and/or Léon Bérard Cancer centre (Rhône-
Alpes region, France) in 2005/2006 or in public hospitals of Veneto (Italy) in 2007.
The time horizon was three years post diagnosis. The hospital’s perspective was
adopted, based on a microcosting approach. All costs were expressed in euros 2009.
A 4% annual discount rate was applied to both costs and effects. Incremental Cost
Effectiveness Ratios (ICER) were expressed as costs per life year gained, per disease-
free year gained, and per relapse-free year gained when treatments were compli-
ant with CPG compared to not compliant. Probabilistic sensitivity analyses were
performed based on 10000 bootstrap replications both with and without adjusting
data to grade. RESULTS: A total of 219 patients were included in the study. Com-
pliance with CPG was observed for 118 patients (54%). Average total costs reached
€23,571 when treatment was in accordance with CPG and €27,313 otherwise. Com-
pliance with CPG strictly dominates for disease-free and relapse-free survivals.
When handling uncertainty, probabilities that compliance with CPG still strictly
dominates were 33%, 63% and 88% for overall, disease-free, and relapse-free sur-
vivals, respectively. When costs and effects were adjusted to grade, probabilities
reached 17%, 48% and 75%, respectively. CONCLUSIONS: Given that few cost-ef-
fectiveness analyses have examined compliance with CPG in rare tumours, these
results are promising and should encourage physicians’ efforts to increase their
compliance to CPG.
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OBJECTIVES: To estimate the cost-effectiveness of G-CSF PP strategies versus peg-
filgrastim SP and G-CSF SP strategies versus no prophylaxis for decreasing FN
incidence in patients treated with cytotoxic chemotherapy for stages 2 and 3 breast
cancer. METHODS: A Markov model was designed to track health outcomes (FN
events) and medical direct costs (G-CSF, administration and FN episode costs, cal-
culated with French Sickness Fund perspective). The model compared 9 prophy-
laxis strategies for three frequent BC chemotherapies (TAC [docetaxel, doxorubi-
cin, cyclophosphamide], TC [docetaxel, cyclophosphamide] and AC-T
[doxorubicin, cyclophosphamide—docetaxel]): pegfilgrastim (Neulasta®), 6-day
filgrastim (Neupogen®), 11-day filgrastim, 6-day lenograstim, as either PP (initiated
from first cycle) or SP (initiated after FN event), or no prophylaxis. Inputs included
transition probabilities (relative FN risks depending on the chemotherapy, deter-
mined from expert opinion and published studies: TAC, 25%; TC, 10% and AC-T 7%
for AC and 21% for T), FN history and chemotherapy cycle), as well as unit costs for
prophylaxis resources and overall cost associated with FN. Incremental cost-effec-
tiveness ratios (ICERs) were expressed per FN event avoided. PP strategies were
compared to SP with pegfilgrastim and SP strategies were compared to no
prophylaxis. RESULTS: In the high risk population (chemotherapy FN risk 20%),
PP-pegfilgrastim was the most cost-effective PP-G-CSF versus SP-pegfilgrastim.
With TAC, ICER was €8,383 per FN avoided. In less cytotoxic regimens without
considering patient risk factors, after an FN event, SP-pegfilgrastim was the most
cost-effective SP-G-CSF compared to no prophylaxis, with ICERS ranging from
€4614 with TC to €4795 with AC-T.CONCLUSIONS:According to our model based on
French cost data, pegfilgrastim in PP and SP is more cost-effective than PP and SP
with filgrastim and lenograstim in BC. PP-pegfilgrastim is the most cost-effective PP
strategy in case of high risk of FN.
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OBJECTIVES: Colorectal cancer (CRC) is one of the most prevalent forms of cancer
worldwide. This review aims to report on the most recent clinical and cost-effec-
tiveness data available for five of the most often used drugs in the treatment of
advanced (ACRC) and non-advanced CRC; oxaliplatin, irinotecan, bevacizumab,
panitumumab and cetuximab. METHODS: A systematic review of the literature
was performed for the clinical effectiveness. Articles were divided on type of CRC,
ACRC or non-advanced CRC , and for ACRC on time point of treatment (1st, 2nd or
3rd line). If possible, data on overall survival (OS) and progression free survival (PFS)
were extracted. An additional systematic review was performed to identify cost-
effectiveness analyses performed for non-advanced CRC and ACRC, from which
total costs, total gains (LYG or QALYs) and ICERs were extracted. RESULTS: Regard-
ing clinical effectiveness, our search identified seven articles for oxaliplatin, six for
irinotecan, four for bevacizumab five for cetuximab and four for panitumumab.
The cost-effectiveness search yielded 6 articles for non-advanced CRC and 17 arti-
cles for ACRC. Clinical effectiveness has been demonstrated in the literature for
oxaliplatin, irinotecan and bevacizumab, with on average approximately two to
three months additional survival. Effectivness of panitumumab and cetuximab has
mainly been demonstrated on PFS, where on average 2 months is gained. The ICERs
of oxaliplatin for non-advanced CRC were between £2,970 and $24,104/QALY. ICERs
reported oxaliplatin and irinotecan combination therapy vs monotherapy with
5-FUin ACRC are between $10,137/LYG and £58.400/progression free LYG. ICERs for
bevacizumab, cetuximab and panitumub in addition to combination chemother-
apy in advanced CRC, when reported, are between €17.000/LYG and $299,613/QALY
CONCLUSIONS: Clinical effectiveness of oxaliplatin, irinotecan, bevacizumab, ce-
tuximab and panitumab has been established. However, it is not clear whether the
use of these drugs is also cost-effective, especially not for bevacizumab, cetuximab
and panitumumab.
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OBJECTIVES: Weekly gemcitabin and erlotinib are both active in elderly patients
treated for NSCLC. The aim of the GFPC0505 randomized phase II trial was to
compare the efficacy and the cost of weekly gemcitabin (G) followed by erlotinib
after progression (arm A) versus erlotinib followed by G after progression (arm B) in
frail elderly patients with advanced non small-cell lung cancer (NSCLC), selected
on the basis of a comprehensive geriatric assessment (CGA). METHODS: Frail el-
derly chemotherapy-naive patients with stage IIIB/IV NSCLC were selected after a
CGA. Main clinical outcome was time to second progression (TTP2). Costs were
limited to direct medical costs and were prospectively collected until progression,
from the third party payer perspective. Health utilities (based on disease states and
grade 3-4 toxicities) and costs after progression were derived from the literature.
Sensitivity analyses were performed. RESULTS: Median age of the 94 enrolled pa-
tients was 78.2 years, and 76 (80%) were male. There is no significantly difference
between the 44 and 50 patients respectively randomized in arm A and B, in terms of
efficacy (TTP2: 4.3 and 3.5 months: overall survival: 4.4 and 3.9 months, mean
QALY:0.347 and 0.325) and in terms of mean direct costs (15,363 and 15,233€).
CONCLUSIONS: In this population, the 2 strategies appeared equivalent in terms of
efficacy and costs. Supported by an unrestricted educational grant from Roche
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OBJECTIVES: To evaluate whether the use of bevacizumab  paclitaxel offers best
cost-effective results regarding the use of paclitaxel for patients with metastatic
breast cancer mBC METHODS: The treatment was evaluated up to the progression
of the disease, rescue management and palliative up to to death in a Markov model,
operating 65 cycles of 28 days. An incremental cost effectiveness analysis and
sensitivity analysis was performed considering as an outcome measure progres-
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sion-free survival (PFS), on the cohort of 2000 patients with Her2 Ne mBC negative
and a subanalysis of the populations of patients with triple negative of patients
with Her2 Neu Negative, taking into account direct medical costs and social costs
due to premature death, in a horizon of 5 years (discount rate 5%). RESULTS: The
40.35% of patients survived after 12 months using bevacizumab paclitaxel, while
only 35.20% did so with only administered paclitaxel. 59.6% of these patients were
PFS with combination therapy, while 37.71% did with monotherapy. Combined
therapy provides more effectiveness than monotherapy in terms of overall sur-
vival, progression-free survival (PFS) and therapeutic response. The incremental
cost of bevacizumab  paclitaxel is $9,639 USD obeying the PFS difference in time
between the two cohorts, and higher consumption on the combination versus
monotherapy. For triple negative subpopulation, the ICER is $2295 USD while for
the sub-population of HER 2 is $1854 USD. The ICER is compared against a threshold
of 3 times GDP per capita in Mexico. The ICER is lower than the threshold, so it is
cost-effective CONCLUSIONS: The combination of bevacizumab  paclitaxel, for
all cases studied, represents a better alternative cost effective versus paclitaxel
monotherapy.
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OBJECTIVES: : One-year adjuvant trastuzumab therapy increases disease-free and
overall survival in the adjuvant treatment of early HER2-positive breast cancer.
This study aims to assess the long-term cost-effectiveness of adjuvant trastu-
zumab treatment in Colombia METHODS: A Markov health-state transition model
was constructed to simulate the natural development of breast cancer in women
with HER2/neu-positive after 12 months of after trastuzumab adjuvant chemother-
apy over a lifetime perspective with annual transition cycles. The model incorpo-
rated five broad health states (disease-free, local recurrence [LCR], distant recur-
rence [DCR], cardiac failure, death). Baseline event rates and 3-year relative risk
(RR 0.75) were derived from the HERA trial. Costs and utility weights were from
the literature and were discounted by 3% annually RESULTS: On the basis of HERA
data, the model results showed that the utilization of adjuvant trastuzumab treat-
ment in early breast cancer can prolong 8.23 quality-adjusted life-years, compared
with 7, 78 quality-adjusted life-years in the standard chemotherapy group. The
incremental cost-effectiveness ratio was US$134,581. Results are moderately sen-
sitive to variation of relative risk, cost and number of cycles of trastuzumab and
less sensitive to breast cancer survival rates and variations in cardiac toxicity
CONCLUSIONS: The results suggest that the 1-year adjuvant trastuzumab treat-
ment is not cost-effective in Colombia. Both clinical and economic benefits were
not superior for the 1-year adjuvant trastuzumab treatment group compared with
the standard adjuvant chemotherapy group
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OBJECTIVES: To investigate the cost-effectiveness of the addition of trastuzumab
in a docetaxel monotherapy for women with HER2 metastatic breast cancer
(MBC) in the Greek healthcare setting.METHODS:A 3-state model was constructed
to simulate progression of the disease and overall quality adjusted survival for
patients receiving trastuzumab and docetaxel (TD) or docetaxel alone (D). The
model ran on 1-month cycles and simulated the progress of patients over a total
period of 12 years. Data on effectiveness were derived from a randomized con-
trolled trial comparing the outcomes of six cycles of docetaxel 100 mg/m2 every 3
weeks, with or without trastuzumab 4 mg/kg loading dose followed by 2 mg/kg
weekly until disease progression in women with an average age of 53 years, and an
average body surface area of 1.7148m2. Costs were estimated from a third-party
payer perspective (2011 Euros), discounted at 3%/annum. RESULTS: Patients in the
TD arm had a mean incremental gain of 0.729 years (95% CI: 0.10, 1.36) in overall
survival and 0.449 (95% CI: 0.14 0.76) QALYs in quality-adjusted survival than those
in the D arm (1.992 vs. 1.542). Taking into account the average incremental cost of
30,474.62€ (95% CI: 23,592.04, 38,195.93) in the TD arm, the analysis reveals that
the Incremental Cost Effectiveness Ratios (ICERs) are estimated at 41,811.13€ and
67,824.92 for every life year or QALY, respectively, gained with trastuzumab. The
probabilistic sensitivity analysis showed that the ICERs produced by TD were
favourable at 17.1% of the Monte Carlo simulations at the 50,000€ and 35.7% at the
60,000€ threshold. CONCLUSIONS: The addition of trastuzumab to a first line treat-
ment of HER2 MBC with docetaxel represents an intervention with a high prob-
ability of being cost-effective from a third party-payer perspective
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OBJECTIVES: This study was performed to evaluate the cost-effectiveness of three
kinds of combination therapies including class II anti-cancer drugs in patients with
advanced or metastatic gastric cancer. METHODS: A Markov model was simulated
to assess the clinical and economic impact over 5 years from societal perspective.
Life Years Gained(LYG) were measured as a clinical outcome. In the model,
Docetaxelcisplatin5-FU(DCF), S-1cisplatin(SP), Capecitabinecisplatin(XP)
were selected as 1st line chemotherapies. When the disease progressed in the
second line therapy, Leucovorin 5-FU Irinotecan (FOLFIRI), it was assumed that
best supportive care was performed. Transition probabilities and mortality were
calculated by using adjusted parameter of “time to progression(TTP) or progression
free survival(PFS), overall survival(OS)”, which were obtained by indirect compar-
ison (control group: 5-FU  Cisplatin). Both direct medical costs and direct non-
medical costs were calculated. Costs and outcomes were discounted at an annual
rate of 5% and sensitivity analysis was performed to evaluate uncertainty in the
results. RESULTS: SP was dominated by XP because the total LYG per patient was
higher and cost was lower for XP compared with SP. When DCF was compared with
XP, incremental LYG was 0.045. However, incremental cost of DCF was also
10,719,975 KRW. Incremental cost-effectiveness ratio for DCF compared to XP was
calculated over 200 million per LYG. The results of the sensitivity analysis showed
no significant difference. CONCLUSIONS: Although a threshold of ICER is not fixed
in Korea, GDP per capita is usually used for reference. In that case, it is considered
that XP is cost-effective compared with DCF. Therefore, XP is the more cost-effec-
tive than DCF and SP. Further research should be carried out about cost-utility by
using utility weight according to the state of gastric cancer.
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OBJECTIVES: The incidence of cervical cancer in Spain is about 10/100,000 women
per year, one of the lowest in Europe. Screening programs and the population
vaccination against HPV are the two health care interventions aiming to reduce
cancer development.The objective of this study is to analyse the efficiency of the
population vaccination program in Spanish girls aged 11-14. METHODS: A simula-
tion discrete event model with a horizon of 20 years, under the perspective of the
National Health System, applied to the context of a high level of coverage Spanish
region (La Rioja) was developed. The cytological results of the population screening
program (14,760 women) and a review of literature on Spanish papers as well as
official statistics were used in the model. Finally, the model took also into account
the impact of some progression co-factors and the decrease on the immunity along
time. RESULTS: According to the model outputs, from the 2725 girls of the first
vaccination camping, 38.2% will not get infected by the HPV, 56.1% will clear the
virus in a spontaneous way, 3.8% will either not progress or do not confirm the
diagnoses, and, consequently, 1.9% would confirm a cervical lesion (29 LSIL and 23
HSIL), without considering the vaccination effect.A population vaccination pro-
gram (that reached a 97.5% coverage) vs no vaccination at all will have an Incre-
mental Cost Effectiveness Ratio of 43,657.8 euros per avoided pre-cancer cervical
lesion. CONCLUSIONS: Although some primary preventative measures are conve-
nient from a public health perspective, their final health and economic outcomes
should be analysed. According to the results of this study, targeting only some risk
populations should be considered as a way of increasing the low efficiency of the
general population vaccination program.
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OBJECTIVES: To analyze cost-effectiveness of a human papillomavirus (HPV) vac-
cination of boys at age 12 against oropharyngeal carcinoma and anogenital warts.
METHODS:We developed Markov decision model for a population of boys of age 12.
We assessed the following outcomes: costs, gains in quality adjusted life years
(QALYs), incremental cost-effectiveness ratio (ICER) for two options: vaccination
with quadrivalent vaccine and no vaccination, and for the two currently-available
vaccination choices: one with quadrivalent vaccine and one with bivalent vaccine.
We employed Monte Carlo microsimulation in the analysis of results. RESULTS:
Comparison of HPV vaccination of boys at age 12 vs. no vaccination resulted in ICER
of 109,384 GBP per QALY. The outcome was sensitive to the vaccination costs, the
probability of developing oropharyngeal carcinoma and anogenital warts, and pro-
portion of oropharyngeal carcinoma attributable to infection with types HPV-16
and HPV-18. When comparing quadrivalent and bivalent vaccines, resulting ICER
was 5,205 GPB per QALY. CONCLUSIONS:Our results indicate that HPV vaccination
of boys with quadrivalent vaccine is at present deemed not cost-effective, i.e., ICER
exceeds willingness-to-pay threshold of 30,000 GBP per QALY. Comparison of
quadrivalent and bivalent vaccines revealed that the additional benefits of protec-
tion against anogenital warts would favour quadrivalent vaccine as the vaccination
choice. An increase in incidence of HPV-positive oropharyngeal carcinoma and
anogenital warts, and reduction of vaccination costs could substantially reduce
ICER. Results of our study have potential healthcare policy implications for HPV
national immunisation programs in the UK and other jurisdictions of developed
countries.
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